# The Longevity Fund

> The Longevity Fund is a VC fund backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 23
- Last investment: Feb 2026
- Lead investor: 4%
- Fund size: $22M
- Last fund: Jun 2017
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/the-longevity-fund-/about/
- Website: http://longevity.vc/

The Longevity Fund is a VC fund in San Francisco focused on Biotechnology and Health Care. The Longevity Fund is investing in human longevity.

## Contacts

5 contacts available for The Longevity Fund. Shizune tracks 4 team members at The Longevity Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/the-longevity-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 70% |
| Health Care | 14 | 61% |
| Medical | 5 | 22% |
| Pharmaceutical | 5 | 22% |
| Biopharma | 4 | 17% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 43% |
| Series A | 8 | 35% |
| Series C | 3 | 13% |
| Series B | 2 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 18 | 78% |
| Israel | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Austin Diamond | VP of Operations | 0 | https://shizune.co/investors/profile/austin-diamond |
| Celine Halioua | Venture Partner | 0 | https://shizune.co/investors/profile/celine-halioua |
| Laura Deming | General Partner | 2 | https://shizune.co/investors/profile/laura-deming-2 |
| Lily Clayton | Head of Operations | 0 | https://shizune.co/investors/profile/lily-clayton |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Loyal | Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $100M | Series C | Feb 11, 2026 |  |
| Loyal | Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $27M | Series A | Sep 23, 2021 |  |
| Edocate | Edocate's platform enables its customers to create unique content in a form of virtual patient cases in a variety of therapeutic areas, to engage healthcare professionals. The platform provides valuable insights into HCP decision-making, clinical gaps and variability in care, prescription patterns, guideline compliance and patient outcomes. | $3M | Seed | Apr 29, 2021 |  |
| Circumvent | Circumvent Pharmaceuticals is seeking to address the significant unmet need of neurodegenerative disease patients. Circumvent is targeting heritable forms of neurodegeneration to enable drug discovery and development in both rare and common forms of neurodegenerative disease. Circumvent is funded by NIH/NINDS, YC Bio, Heritage ProviderNetwork, the Longevity Fund, and additional investors. | $4.1M | Seed | Dec 09, 2020 |  |
| Rubedo Life Sciences | Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $12M | Seed | Dec 03, 2020 |  |
| Elevian | Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues. Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease. | $15M | Seed | Nov 24, 2020 |  |
| Wellth | Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence inchronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale.In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com. | $1.5M | Series A | Jun 19, 2020 |  |
| Celevity | Celevity is a seed-stage company that develops drugs to help dogs live longer, healthier lives. It sees aging as a disease that is able to be slowed and improved with medicines. It was spun out of Laura Deming’s The Longevity Fund. Celevity is headquartered in San Francisco, California. | $4.9M | Seed | Jan 03, 2020 |  |
| Loyal | Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $11M | Seed | Jan 01, 2020 |  |
| Epirium Bio | Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function. | $85M | Series A | Dec 18, 2019 |  |

10 of 23 investments shown.

## Co-investors
- [First Round Capital](https://shizune.co/investors/profile/first-round-capital) — VC Fund, 3 deals together
- [venBio Partners](https://shizune.co/investors/profile/venbio) — VC Fund, 3 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 2 deals together
- [Baillie Gifford](https://shizune.co/investors/profile/baillie-gifford) — VC Fund, 2 deals together
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 2 deals together
- [Boom Capital](https://shizune.co/investors/profile/boom-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Reach Capital](https://shizune.co/investors/profile/reach-capital) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [GSV Ventures](https://shizune.co/investors/profile/gsv-acceleration) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Education VC Funds in Israel](https://shizune.co/investors/education-vc-funds-israel)
- [EdTech VC Funds in Israel](https://shizune.co/investors/edtech-vc-funds-israel)

## FAQ

### What does The Longevity Fund invest in?

The Longevity Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact The Longevity Fund?

Public channels for The Longevity Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at The Longevity Fund?

The team at The Longevity Fund includes Austin Diamond (VP of Operations), Celine Halioua (Venture Partner) and Laura Deming (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co